ReportWire

Tag: Gilead Sciences

  • A Diagnosis, A Decade, and the Weight of Stigma

    [ad_1]

    On a warm Florida night in May 2013, Christopher “Super” Green learned he was HIV-positive.

    “I got my diagnosis on a date, actually,” he said. “I was dating a guy, and we wanted to be intimate. He was studying public health, so we went to a clinic together.”

    The result stunned him. Just months earlier, he had tested negative. “I remember feeling like my world had ended,” Green said. “At this point, I felt like my life was over. No one was going to love me. This is it. Get ready. I have three years to live.”

    Christopher Green, 34, has been on antiretroviral medication since being diagnosed with HIV a decade ago. The medication provides a healthy life and suppresses the virus, so he is undetectable and cannot transmit it. Photo by Dyana Bagby/The Atlanta Voice

    Those early days were marked by fear and shame. Shame made him feel isolated, unwanted, untouchable. But Green’s best friend, T.J., promised to stand by him. That support, combined with meeting J.J.—a young, Black case manager who spoke his language and understood his experiences—shifted everything. J.J. inspired Green to pursue public health himself.

    Ten years later, Green is thriving. He works as a lead prevention navigator at Here’s to Life, a nonprofit in Atlanta’s West End serving men with HIV and substance use disorders. He tells his story openly because silence, he said, only fuels stigma.

    “For many people, the stigma is more dangerous than HIV itself,” Green explained. “It keeps people from getting tested, starting treatment, or reaching out for support.”

    Green’s story mirrors a larger crisis: HIV continues to disproportionately affect Black communities in the South, where systemic inequities drive persistent disparities.

    Structural Inequities

    Nationwide, more than 1.13 million people were living with HIV in 2023, according to AIDSVu, a project of Emory University. Those aged 55–64 made up the largest group, 26%. Black individuals accounted for 39% of people living with HIV—despite being just 12% of the U.S. population. The prevalence rate among Black Americans was seven times higher than among white Americans.

    The disparities start with prevention. In 2023, Black Americans made up 38% of new HIV diagnoses but just 14% of those eligible for PrEP, a highly effective prevention pill.

    “These systemic inequities are the main driver,” said Rashad Burgess, vice president of corporate responsibility at Gilead Sciences. “We’ve known this for a long time, and it’s still true today.”

    Rashad Burgess of Gilead Sciences said systemic health inequities are the primary driver of HIV disparities and the reason HIV disproportionately impacts Black communities. Photo courtesy Gilead Sciences 

    Atlanta is one of the nation’s HIV hotspots, with Fulton County reporting that Black residents account for more than 60% of new diagnoses, though they make up roughly 40% of the population. AIDSVu maps show the hardest-hit neighborhoods concentrated in southwest Atlanta and along the I-20 corridor, areas shaped by housing instability, limited transportation, and scarce access to culturally competent healthcare.

    “Having the ability to get a ride to a doctor’s office is key,” Burgess said. “If you’re unstably housed, it’s hard to stay on medications. And if you’re not virologically suppressed, you’re more likely to transmit the virus and your health outcomes decline.”

    Gaps in Prevention

    Access to PrEP remains one of the biggest gaps. Even when Black patients are engaged in healthcare, Burgess said, they are less likely to be offered PrEP due to provider bias.

    “What we find to be really successful are systems that routinize HIV screening,” he said. “That way, people know their status and, if negative, can be offered PrEP as a natural next step.”

    Longtime Atlanta activist Daniel Driffin said too many providers still refer patients to specialty clinics instead of prescribing PrEP themselves. Combined with high uninsured rates and Georgia’s refusal to expand Medicaid, many fall through the cracks.

    “We’re waiting for people to learn they’re living with HIV before we intervene,” Driffin said. “That’s a horrible place to be in public health.”

    Driffin and other activists launched a community-led prevention model to address the gap. Over 60 days, more than 150 participants helped design a program focused on three pillars: robust HIV testing, a pooled “people’s purse” to fund prevention efforts, and culturally resonant messaging.

    “We create a hand-holding situation until that person begins care,” Driffin said. “Community-led solutions alongside public health oversight ensure that people aren’t being forgotten.”

    Progress and Threats

    Medical advances have made HIV manageable. In 2023, 82.8% of newly diagnosed individuals were linked to care, 76.3% of people living with diagnosed HIV received care, and 67.2% achieved viral suppression.

    “You can live a normal life, have a normal lifespan, with your virus being managed by therapy,” Burgess said.

    But progress is fragile. More than 80% of CDC prevention funding supports state and local health departments through the federal Ending the HIV Epidemic initiative. Proposed cuts of nearly $1.5 billion to Medicaid and CDC budgets could erode years of gains, leading to more infections nationwide.

    The Weight of Stigma

    Even with medicine and prevention tools, stigma remains the hardest barrier to break, particularly in the South.

    “As a matter of fact, many argue stigma is the number one barrier,” Burgess said. “It impacts whether people access PrEP, whether they seek treatment, and whether they’re diagnosed late or with AIDS.”

    To shift perceptions, Gilead invests in campaigns featuring trusted voices—from faith leaders to barbershops to celebrities like Tamar Braxton, who has publicly shared her use of PrEP. Partnerships with Morehouse School of Medicine extend outreach to rural Georgia.

    “We have to normalize HIV prevention and care as part of overall wellness,” Burgess said. “That means visual representation, trusted messengers, and community-driven dialogue.”

    For Green, that mission is personal. Each time he shares his story, he chips away at the silence that once left him isolated.

    “I learned what care looks like from another Black man because he knew how to relate to me, how to pour into me what I needed as opposed to giving me just clinical information,” Green said. 

    “We often talk about the social determinants of health within public health spaces, such as housing, employment, and access to a phone. But we can’t leave out the most important thing, and that is the person and meeting them where they are.” 

    [ad_2]

    Dyana Bagby

    Source link

  • Wall Street says buy stocks that pay dividends with $6 trillion of cash ready to be deployed

    Wall Street says buy stocks that pay dividends with $6 trillion of cash ready to be deployed

    [ad_1]

    Getty Images; Chelsea Jia Feng/BI

    • Dividend stocks are set to surge as investors deploy $6 trillion from money-market funds, Bank of America says.

    • Investors could be looking to invest their cash as the Fed gets ready to cut interest rates in September.

    • BMO agrees, and recommends high-yielding stocks including Abbvie, Chevron, and Gilead Sciences.

    Dividend-paying stocks are poised to surge in the second half of the year as investors start to deploy the $6 trillion sitting in money market funds, according to Bank of America.

    Strategist Savita Subramanian called the dividend trade a “pain trade,” meaning the bulk of investors are not properly positioned for the potential upside gains in dividend-paying stocks.

    “Over $6 trillion sits in US money market funds as the Fed is poised to start cutting rates,” Subramanian said in a note this week. “Bond funds have seen record flows YTD, but we see more opportunities within equities for investors searching for yield.”

    There are more than 200 S&P 500 stocks that offer a higher real return potential than the 2% offered by the 10-year Treasury yield, according to the note, and about 75% of those stocks are under-owned by professional investors.

    Some of the highest-yielding S&P 500 companies include Walgreens Boot Alliance, Altria, Verizon, Ford, and AT&T. And while the S&P 500 as a whole offers a dividend yield of about 1.25%, there are nearly 300 S&P 500 stocks that offer a higher yield.

    “Overall, we expect dividends to make up a larger proportion of returns than the outsized price returns and multiple expansion of the past decade,” Subramanian said.

    BMO’s Brian Belski is another Wall Street strategist who expects big gains to be had from dividend paying stocks, especially after their lackluster performance since the October 2022 stock market bottom.

    “We believe these stocks have turned the corner and recent relative strength is likely to persist in the coming months,” Belski said in a note on Tuesday. “With the Fed now likely to cut rates sooner than previously anticipated, the likely drop in longer-term yields in response should provide a boost.”

    Some of the high-paying dividend stocks recommended by Belski include Abbvie, Chevron, Duke Energy, Gilead Sciences, and Pfizer.

    As investors hunt for yield at a time when interest rates are about to fall, dividend-paying stocks could be the underloved area of the stock market that is set to boom.

    The Fed is expected to make its first interest rate cut of the current cycle at its September FOMC meeting.

    Read the original article on Business Insider

    [ad_2]

    Source link

  • Why Gilead Sciences Stock Got Mashed on Monday

    Why Gilead Sciences Stock Got Mashed on Monday

    [ad_1]

    Pharmaceutical sector mainstay Gilead Sciences (NASDAQ: GILD) has had many good days on the stock exchange, but Monday wasn’t one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company’s share price down by more than 10%. And that was on a day when the bellwether S&P 500 index ended in positive territory, rising almost 0.3%.

    Trodelvy didn’t meet its latest primary endpoint

    That trial was a late-stage one for Trodelvy, an approved cancer medication. Gilead was hoping to expand its Food and Drug Administration (FDA) approval to cover patients with advanced or metastatic non-small cell lung cancer (NSCLC) that had progressed following the administration of platinum-based chemotherapy and checkpoint inhibitor therapy.

    Unfortunately, in the phase 3 study, Trodelvy did not meet its primary endpoint of overall survival (OS) for the drug’s recipients.

    On a brighter note, Gilead said, “A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology.”

    NSCLC is the most common form of lung cancer; thus, the trial’s general results are a setback for that relatively large patient population.

    Gilead quoted its chief medical officer Merdad Parsey as saying that the pharmaceutical company will continue to work toward identifying metastatic NSCLC patents that might benefit from Trodelvy.

    The $21 billion gamble

    Gilead continues to have high ambitions for the cancer drug, which was the star asset in the company’s $21 billion acquisition of peer Immunomedics in 2020. There are other investigational avenues it can pursue in developing the drug, so Monday’s investor reaction feels a bit overblown; Gilead bulls might do well hanging on to their stock despite the sell-off.

    Should you invest $1,000 in Gilead Sciences right now?

    Before you buy stock in Gilead Sciences, consider this:

    The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

    See the 10 stocks

     

    *Stock Advisor returns as of January 22, 2024

     

    Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

    Why Gilead Sciences Stock Got Mashed on Monday was originally published by The Motley Fool

    [ad_2]

    Source link

  • Nations Financial Group Inc. IA ADV Acquires 2,068 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

    Nations Financial Group Inc. IA ADV Acquires 2,068 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

    [ad_1]

    Nations Financial Group Inc. IA ADV lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 60.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,501 shares of the biopharmaceutical company’s stock after purchasing an additional 2,068 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Gilead Sciences were worth $472,000 as of its most recent filing with the SEC.

    Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Bridge LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $30,000. Concord Wealth Partners bought a new stake in Gilead Sciences in the 4th quarter worth $33,000. Hanseatic Management Services Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $37,000. EWG Elevate Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $45,000. Finally, Duncker Streett & Co. Inc. grew its holdings in Gilead Sciences by 266.7% in the 4th quarter. Duncker Streett & Co. Inc. now owns 550 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 78.72% of the company’s stock.

    Insiders Place Their Bets

    In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

    Gilead Sciences Stock Performance

    Shares of GILD stock opened at $78.52 on Friday. The company has a 50 day moving average price of $81.47 and a 200-day moving average price of $82.60. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. The firm has a market capitalization of $98.06 billion, a PE ratio of 17.72, a P/E/G ratio of 0.91 and a beta of 0.38. The company has a quick ratio of 1.08, a current ratio of 1.37 and a debt-to-equity ratio of 1.14.

    Gilead Sciences (NASDAQ:GILDGet Rating) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.26). The business had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $6.33 billion. Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.12 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.75 earnings per share for the current year.

    Gilead Sciences Announces Dividend

    The company also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Thursday, June 15th will be given a $0.75 dividend. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.82%. Gilead Sciences’s payout ratio is currently 67.72%.

    Analyst Upgrades and Downgrades

    A number of equities research analysts have issued reports on the stock. Mizuho raised their price target on shares of Gilead Sciences from $88.00 to $101.00 and gave the stock a “buy” rating in a report on Tuesday, February 14th. Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 18th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 12th. Piper Sandler lifted their target price on shares of Gilead Sciences from $111.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. Finally, StockNews.com initiated coverage on shares of Gilead Sciences in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.60.

    Gilead Sciences Company Profile

    (Get Rating)

    Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

    See Also

    Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

    Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

    Receive News & Ratings for Gilead Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Apple, Amazon, Alphabet, Ford, Nordstrom, and More Stock Market Movers

    Apple, Amazon, Alphabet, Ford, Nordstrom, and More Stock Market Movers

    [ad_1]


    • Order Reprints

    • Print Article


    [ad_2]

    Source link

  • Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

    Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

    [ad_1]

    Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon.

    With reality setting in, it’s a buyer’s market for companies looking for acquisitions and partnerships, according to many of the pharmaceutical and medical technology executives who gathered at this year’s


    J.P. Morgan


    healthcare investor conference, which wrapped up in San Francisco on Thursday.

    [ad_2]

    Source link